Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.

Abstract

BACKGROUND The new anti-cancer drug imatinib mesylate inhibits the tyrosine kinase growth factor receptor, c-KIT, and has shown spectacular activity in patients with gastrointestinal stromal tumours (GISTs). OBJECTIVE To assess whether fluorodeoxyglucose positron emission tomography (FDG PET) is suitable for response evaluation of this new type of tumour… (More)

Topics

Cite this paper

@article{Jager2004ImatinibMF, title={Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.}, author={Pieter L. Jager and Jourik A. Gietema and Winette T A van der Graaf}, journal={Nuclear medicine communications}, year={2004}, volume={25 5}, pages={433-8} }